Silvercrest Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.2M Sell
108,246
-2,254
-2% -$485K 0.18% 161
2026
Q1
$24M Sell
110,500
-14,540
-12% -$3.23M 0.17% 162
2025
Q4
$28.6M Buy
125,040
+152
+0.1% +$34.6K 0.2% 139
2025
Q3
$28.9M Sell
124,888
-603
-0.5% -$123K 0.19% 149
2025
Q2
$23.3M Sell
125,491
-5,452
-4% -$1.01M 0.16% 181
2025
Q1
$27.4M Buy
130,943
+5,231
+4% +$1.02M 0.2% 145
2024
Q4
$22.3M Sell
125,712
-22,241
-15% -$4.09M 0.15% 174
2024
Q3
$29.2M Sell
147,953
-422
-0.3% -$78.8K 0.2% 153
2024
Q2
$25.4M Sell
148,375
-4,152
-3% -$688K 0.17% 165
2024
Q1
$27.8M Sell
152,527
-19,399
-11% -$3.34M 0.19% 156
2023
Q4
$26.6M Sell
171,926
-1,494
-0.9% -$218K 0.19% 154
2023
Q3
$25.9M Sell
173,420
-4,489
-3% -$659K 0.2% 151
2023
Q2
$24M Sell
177,909
-4,782
-3% -$701K 0.17% 159
2023
Q1
$29.1M Sell
182,691
-950
-0.5% -$145K 0.22% 136
2022
Q4
$29.7M Sell
183,641
-2,554
-1% -$392K 0.23% 133
2022
Q3
$25M Sell
186,195
-733
-0.4% -$105K 0.21% 143
2022
Q2
$28.6M Sell
186,928
-4,104
-2% -$627K 0.22% 140
2022
Q1
$31M Sell
191,032
-453
-0.2% -$65.8K 0.2% 144
2021
Q4
$25.9M Sell
191,485
-2,879
-1% -$340K 0.16% 159
2021
Q3
$21M Sell
194,364
-1,845
-0.9% -$211K 0.14% 179
2021
Q2
$22.1M Buy
196,209
+803
+0.4% +$90.4K 0.15% 179
2021
Q1
$21.1M Sell
195,406
-2,817
-1% -$301K 0.14% 176
2020
Q4
$21.2M Sell
198,223
-3,425
-2% -$329K 0.16% 164
2020
Q3
$17.7M Sell
201,648
-6,911
-3% -$651K 0.15% 161
2020
Q2
$20.5M Buy
208,559
+11,553
+6% +$1.02M 0.18% 146
2020
Q1
$15M Buy
197,006
+4,824
+3% +$411K 0.16% 155
2019
Q4
$17M Sell
192,182
-1,246
-0.6% -$103K 0.13% 170
2019
Q3
$14.6M Sell
193,428
-1,749
-0.9% -$120K 0.12% 183
2019
Q2
$14.2M Sell
195,177
-926
-0.5% -$72.8K 0.13% 156
2019
Q1
$15.8M Sell
196,103
-1,779
-0.9% -$146K 0.16% 151
2018
Q4
$18.2M Sell
197,882
-10,886
-5% -$957K 0.2% 138
2018
Q3
$19.7M Sell
208,768
-1,356
-0.6% -$129K 0.18% 143
2018
Q2
$19.5M Sell
210,124
-2,893
-1% -$283K 0.18% 144
2018
Q1
$20.2M Sell
213,017
-2,195
-1% -$241K 0.2% 138
2017
Q4
$20.8M Sell
215,212
-4,246
-2% -$400K 0.19% 138
2017
Q3
$19.5M Sell
219,458
-6,453
-3% -$491K 0.19% 135
2017
Q2
$16.4M Sell
225,911
-4,530
-2% -$305K 0.18% 140
2017
Q1
$15M Sell
230,441
-3,916
-2% -$246K 0.16% 145
2016
Q4
$14.7M Sell
234,357
-246
-0.1% -$15K 0.16% 140
2016
Q3
$14.8M Sell
234,603
-2,705
-1% -$175K 0.18% 138
2016
Q2
$14.7M Buy
237,308
+5,100
+2% +$311K 0.19% 138
2016
Q1
$13.3M Sell
232,208
-7,770
-3% -$433K 0.18% 141
2015
Q4
$14.2M Buy
239,978
+24,515
+11% +$1.41M 0.2% 137
2015
Q3
$11.7M Sell
215,463
-23,671
-10% -$1.54M 0.18% 137
2015
Q2
$16.1M Buy
239,134
+14,621
+7% +$955K 0.21% 127
2015
Q1
$13.1M Sell
224,513
-3,075
-1% -$186K 0.19% 138
2014
Q4
$14.9M Sell
227,588
-2,400
-1% -$151K 0.22% 124
2014
Q3
$13.3M Sell
229,988
-1,980
-0.9% -$110K 0.21% 131
2014
Q2
$13.1M Sell
231,968
-215
-0.1% -$11.3K 0.2% 131
2014
Q1
$11.9M Sell
232,183
-2,735
-1% -$138K 0.19% 131
2013
Q4
$12.4M Sell
234,918
-300
-0.1% -$14.7K 0.21% 127
2013
Q3
$10.5M Sell
235,218
-2,100
-0.9% -$93.1K 0.2% 127
2013
Q2
$9.81M Buy
+237,318
New +$10.4M 0.21% 122

Other funds holding ABBV

Silvercrest Asset Management's ABBV Position: Q2 2026 in Review

Silvercrest Asset Management reduced its AbbVie (ABBV) stake by 2% in Q2 2026, selling an estimated $485K and leaving 108,246 shares worth $27.2M. The position accounts for 0.18% of the portfolio, ranked #161.

Silvercrest Asset Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $31M in Q1 2022. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Silvercrest Asset Management held 108,246 shares of AbbVie worth $27.2M as of Q2 2026.
  • Silvercrest Asset Management sold 2,254 AbbVie shares in Q2 2026, an estimated $485K.
  • AbbVie made up 0.18% of Silvercrest Asset Management's portfolio in Q2 2026, its #161 holding.
  • Silvercrest Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Silvercrest Asset Management's AbbVie position peaked at $31M in Q1 2022.
  • 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.